{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:06:11Z","timestamp":1790708771195,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.canep.2023.102352","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T10:15:41Z","timestamp":1679480141000},"page":"102352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Quantification of overdiagnosis in randomised trials of cancer screening: an overview and re-analysis of systematic reviews"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4736-6950","authenticated-orcid":false,"given":"Theis","family":"Voss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikela","family":"Krag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Martiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Heleno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten Juhl","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Brandt Brodersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.canep.2023.102352_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/apm.12278","article-title":"Overdiagnosis: how cancer screening can turn indolent pathology into illness","volume":"122","author":"Brodersen","year":"2014","journal-title":"Apmis"},{"key":"10.1016\/j.canep.2023.102352_bib2","doi-asserted-by":"crossref","first-page":"f5334","DOI":"10.1136\/bmj.f5334","article-title":"Quantification of harms in cancer screening trials: literature review","volume":"347","author":"Heleno","year":"2013","journal-title":"Bmj"},{"issue":"1","key":"10.1016\/j.canep.2023.102352_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1472-6874-9-36","article-title":"Overdiagnosis in organised mammography screening in Denmark. A comparative study","volume":"9","author":"J\u00f8rgensen","year":"2009","journal-title":"BMC Women'S. Health"},{"issue":"4","key":"10.1016\/j.canep.2023.102352_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/M15-2886","article-title":"Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement","volume":"164","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"10.1016\/j.canep.2023.102352_bib5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jnci\/djq099","article-title":"Overdiagnosis in cancer","volume":"102","author":"Welch","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"issue":"21","key":"10.1016\/j.canep.2023.102352_bib6","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1001\/archinte.167.21.2289","article-title":"Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study","volume":"167","author":"Welch","year":"2007","journal-title":"Arch. Intern Med"},{"key":"10.1016\/j.canep.2023.102352_bib7","doi-asserted-by":"crossref","first-page":"g7773","DOI":"10.1136\/bmj.g7773","article-title":"Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods","volume":"350","author":"Carter","year":"2015","journal-title":"Bmj"},{"issue":"12","key":"10.1016\/j.canep.2023.102352_bib8","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(07)70380-7","article-title":"Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review","volume":"8","author":"Biesheuvel","year":"2007","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.canep.2023.102352_bib9","article-title":"Screening for breast cancer with mammography","volume":"2013","author":"G\u00f8tzsche","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.canep.2023.102352_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/epirev\/mxr009","article-title":"Interpreting overdiagnosis estimates in population-based mammography screening","volume":"33","author":"de Gelder","year":"2011","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.canep.2023.102352_bib11","unstructured":"T. Voss MK, B. Heleno, K.J. J\u00f8rgensen, F. Martiny, J. Brodersen. Quantification of overdiagnosis in randomised trials of cancer screening: an overview and re-analysis of systematic reviews. crdyorkacuk\/prospero\/. 2019."},{"key":"10.1016\/j.canep.2023.102352_bib12","unstructured":"Team TE Endnote. EndNote X9 ed. Philadelphia, PA: Clarivate; 2013."},{"key":"10.1016\/j.canep.2023.102352_bib13","unstructured":"Corporation M.. Microsoft Excel. Microsoft Exel, Microsoft 365. 2018 ed: Microsoft Corporation; 2018."},{"key":"10.1016\/j.canep.2023.102352_bib14","unstructured":"Higgins J.P.T. AD, Sterne JAC. Assessing risk of bias in included studies: The Cochrane Collaboration; 2011 [updated updated March 2011. 5.1.0 [Available from: www.cochrane-handbook.org."},{"issue":"1","key":"10.1016\/j.canep.2023.102352_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/13814788.2017.1290795","article-title":"How to conduct research on overdiagnosis. A keynote paper from the EGPRN May 2016, Tel Aviv","volume":"23","author":"Brodersen","year":"2017","journal-title":"Eur. J. Gen. Pr."},{"key":"10.1016\/j.canep.2023.102352_bib16","doi-asserted-by":"crossref","first-page":"k3519","DOI":"10.1136\/bmj.k3519","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"Ilic","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.canep.2023.102352_bib17","first-page":"147","article-title":"Overdiagnosis: An Unrecognised and Growing Worldwide Problem in Healthcare","volume":"56","author":"Brodersen","year":"2017","journal-title":"Zdr. Varst."},{"issue":"11","key":"10.1016\/j.canep.2023.102352_bib18","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/bjc.2013.177","article-title":"The benefits and harms of breast cancer screening: an independent review","volume":"108","author":"Marmot","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canep.2023.102352_bib19","unstructured":"Team RC. R: A Language and Environment for Statistical Computing. 2013."},{"key":"10.1016\/j.canep.2023.102352_bib20","unstructured":"Review Manager (RevMan) 5.3 ed. Copenhagen:: The Nordic Cochrane Centre. The Cochrane Collaboration; 2014."},{"issue":"6","key":"10.1016\/j.canep.2023.102352_bib21","article-title":"Screening for reducing morbidity and mortality in malignant melanoma","volume":"6","author":"Johansson","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.canep.2023.102352_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/thoraxjnl-2016-209825","article-title":"Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial","volume":"72","author":"Paci","year":"2017","journal-title":"Thorax"},{"issue":"10290","key":"10.1016\/j.canep.2023.102352_bib23","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.canep.2023.102352_bib24","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.juro.2008.11.115","article-title":"15-year followup of a population based prostate cancer screening study","volume":"181","author":"Kjellman","year":"2009","journal-title":"J. Urol."},{"issue":"18","key":"10.1016\/j.canep.2023.102352_bib25","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/jnci\/92.18.1490","article-title":"Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years","volume":"92","author":"Miller","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2023.102352_bib26","doi-asserted-by":"crossref","unstructured":"Miller A.B., To T., Baines C.J., Wall C.. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med. 2002;137(5 Part 1):305\u201312.","DOI":"10.7326\/0003-4819-137-5_Part_1-200209030-00005"},{"key":"10.1016\/j.canep.2023.102352_bib27","doi-asserted-by":"crossref","first-page":"g366","DOI":"10.1136\/bmj.g366","article-title":"Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ","volume":"348","author":"Miller","year":"2014","journal-title":"Br. Med. J."},{"key":"10.1016\/j.canep.2023.102352_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jncimono\/1997.22.63","article-title":"Reduced breast cancer mortality in women under age 50: updated results from the Malm\u00f6 Mammographic Screening Program","volume":"22","author":"Andersson","year":"1997","journal-title":"J. Natl. Cancer Inst. Monogr."},{"issue":"7543","key":"10.1016\/j.canep.2023.102352_bib29","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/bmj.38764.572569.7C","article-title":"Rate of over-diagnosis of breast cancer 15 years after end of Malm\u00f6 mammographic screening trial: follow-up study","volume":"332","author":"Zackrisson","year":"2006","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.canep.2023.102352_bib30","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1002\/1097-0142(197706)39:6<2772::AID-CNCR2820390665>3.0.CO;2-K","article-title":"Evidence on screening for breast cancer from a randomized trial","volume":"39","author":"Shapiro","year":"1977","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.canep.2023.102352_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jncimono\/1997.22.27","article-title":"Periodic Screening for Breast Cancer: The HIP Randomized Controlled Trial","volume":"1997","author":"Shapiro","year":"1997","journal-title":"JNCI Monogr."},{"issue":"5","key":"10.1016\/j.canep.2023.102352_bib32","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/sj.bjc.6602396","article-title":"Randomised controlled trial of mammographic screening in women from age 40: results of screening in the first 10 years","volume":"92","author":"Moss","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"9552","key":"10.1016\/j.canep.2023.102352_bib33","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(06)69834-6","article-title":"Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial","volume":"368","author":"Moss","year":"2006","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.canep.2023.102352_bib34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S1470-2045(15)00128-X","article-title":"Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial","volume":"16","author":"Moss","year":"2015","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.canep.2023.102352_bib35","first-page":"257","article-title":"Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial. Rev Recent Clin Trials","volume":"13","author":"Prorok","year":"2018"},{"key":"10.1016\/j.canep.2023.102352_bib36","doi-asserted-by":"crossref","unstructured":"Oken M.M., Hocking W.G., Kvale P.A., Andriole G.L., Buys S.S., Church T.R., et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial. JAMA. 2011;306(17):1865\u201373.","DOI":"10.1001\/jama.2011.1591"},{"issue":"4","key":"10.1016\/j.canep.2023.102352_bib37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/thoraxjnl-2011-200736","article-title":"CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT","volume":"67","author":"Saghir","year":"2012","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.canep.2023.102352_bib38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial","volume":"382","author":"de Koning","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.canep.2023.102352_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/thoraxjnl-2016-208655","article-title":"Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval","volume":"72","author":"Yousaf-Khan","year":"2017","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.canep.2023.102352_bib40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/CEJ.0b013e328351e1b6","article-title":"Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial","volume":"21","author":"Pastorino","year":"2012","journal-title":"Eur. J. Cancer Prev."},{"issue":"7","key":"10.1016\/j.canep.2023.102352_bib41","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/annonc\/mdz117","article-title":"Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy","volume":"30","author":"Pastorino","year":"2019","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.canep.2023.102352_bib42","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ijc.33295","article-title":"Overdiagnosis in lung cancer screening: Estimates from the German Lung Cancer Screening Intervention Trial","volume":"148","author":"Gonz\u00e1lez Maldonado","year":"2021","journal-title":"Int J. Cancer"},{"issue":"7","key":"10.1016\/j.canep.2023.102352_bib43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canep.2023.102352_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.canep.2023.102352_bib45","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.eururo.2004.08.011","article-title":"Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden","volume":"46","author":"Sandblom","year":"2004","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canep.2023.102352_bib46","doi-asserted-by":"crossref","first-page":"d1539","DOI":"10.1136\/bmj.d1539","article-title":"Randomised prostate cancer screening trial: 20 year follow-up","volume":"342","author":"Sandblom","year":"2011","journal-title":"Bmj"},{"issue":"13","key":"10.1016\/j.canep.2023.102352_bib47","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.canep.2023.102352_bib48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.canep.2023.102352_bib49","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bju.14580","article-title":"Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial","volume":"123","author":"Pinsky","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.canep.2023.102352_bib50","first-page":"182","article-title":"Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival","volume":"87","author":"Temkin","year":"2017"},{"issue":"9160","key":"10.1016\/j.canep.2023.102352_bib51","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(98)10261-1","article-title":"Screening for ovarian cancer: a pilot randomised controlled trial","volume":"353","author":"Jacobs","year":"1999","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.canep.2023.102352_bib52","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S1470-2045(20)30398-3","article-title":"Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial","volume":"21","author":"Duffy","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canep.2023.102352_bib53","doi-asserted-by":"crossref","first-page":"d1539","DOI":"10.1136\/bmj.d1539","article-title":"Randomised prostate cancer screening trial: 20 year follow-up","volume":"342","author":"Sandblom","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.canep.2023.102352_bib54","unstructured":"Force USPST. [Available from: https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/methods-and-processes\/procedure-manual\/procedure-manual-section-4-evidence-review-development."},{"key":"10.1016\/j.canep.2023.102352_bib55","unstructured":"Pollock M.F.R., Becker L.A., Pieper D., Hartling L. Chapter V: Overviews of Reviews. Available from www.training.cochrane.org\/handbook.2022."},{"issue":"7","key":"10.1016\/j.canep.2023.102352_bib56","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1038\/bjc.2013.427","article-title":"Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis","volume":"109","author":"Zahl","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.canep.2023.102352_bib57","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/bcr3427","article-title":"Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time","volume":"15","author":"Duffy","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.canep.2023.102352_bib58","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/aje\/kwv342","article-title":"Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies","volume":"184","author":"Gulati","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.canep.2023.102352_bib59","unstructured":"Deeks J.J.H.J., Altman D.G. (editors). Chapter 10: Analysing data and undertaking meta-analyses. Chapter 10: Analysing data and undertaking meta-analyses. Available from www.training.cochrane.org\/handbook.2022."},{"key":"10.1016\/j.canep.2023.102352_bib60","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jclinepi.2020.09.030","article-title":"Addressing harms of screening - A review of outcomes in Cochrane reviews and suggestions for next steps","volume":"129","author":"Johansson","year":"2021","journal-title":"J. Clin. Epidemiol."},{"issue":"6","key":"10.1016\/j.canep.2023.102352_bib61","article-title":"Screening for lung cancer","volume":"2013","author":"Manser","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1)","key":"10.1016\/j.canep.2023.102352_bib62","article-title":"Screening for prostate cancer","author":"Ilic","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.canep.2023.102352_bib63","unstructured":"Siu A.L. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine; 2016. [Accessed October 2016] Available from https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/UpdateSummaryFinal\/breast-cancer-screening1?ds=1&s=breast%20cancer%20screening."},{"key":"10.1016\/j.canep.2023.102352_bib64","unstructured":"Moyer V.A. Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine; 2013. [accessed October 2016] Available from: https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/UpdateSummaryFinal\/lung-cancer-screening?ds=1&s=lung%20cancer%20screening. [."},{"key":"10.1016\/j.canep.2023.102352_bib65","unstructured":"Moyer V.A.. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine; 2012. [Accessed October 2016] Available from https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/UpdateSummaryFinal\/prostate-cancer-screening?ds=1&s=prostat%20cancer%20screening."},{"issue":"8","key":"10.1016\/j.canep.2023.102352_bib66","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/thoraxjnl-2018-212263","article-title":"Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial","volume":"74","author":"Marcus","year":"2019","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.canep.2023.102352_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003436","article-title":"Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension","volume":"3","author":"Hodkinson","year":"2013","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.canep.2023.102352_bib68","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann. Intern Med"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782123000322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782123000322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:30:36Z","timestamp":1761802236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782123000322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":68,"alternative-id":["S1877782123000322"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2023.102352","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of overdiagnosis in randomised trials of cancer screening: an overview and re-analysis of systematic reviews","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2023.102352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102352"}}